MEK inhibition in advanced thyroid carcinomas

Overview of attention for article published in Frontiers in endocrinology, October 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 5,859 followers.

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas https://t.co/Bnjia9eE41

15 Nov 2023

Reply Repost Favourite

New Research: CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas: Background CDK4/6 inhibitors (CDK4/6i) have been established as standard treatment against… https://t.co/SZvHKBdM9Q #En

26 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.